Cytokinetics (CYTK) Short Interest Ratio & Short Volume $42.42 -0.42 (-0.98%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cytokinetics Short Interest DataCytokinetics (CYTK) has a short interest of 13.95 million shares, representing 12.02% of the float (the number of shares available for trading by the public). This marks a -2.65% decrease in short interest from the previous month. The short interest ratio (days to cover) is 7.2, indicating that it would take 7.2 days of the average trading volume of 1.60 million shares to cover all short positions.Current Short Interest13,950,000 sharesPrevious Short Interest14,330,000 sharesChange Vs. Previous Month-2.65%Dollar Volume Sold Short$537.91 millionShort Interest Ratio7.2 Days to CoverLast Record DateApril 15, 2025Outstanding Shares119,188,000 sharesFloat Size116,040,000 sharesShort Percent of Float12.02%Today's Trading Volume277,384 sharesAverage Trading Volume1,599,685 sharesToday's Volume Vs. Average17% Short Selling Cytokinetics? Sign up to receive the latest short interest report for Cytokinetics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCYTK Short Interest Over TimeCYTK Days to Cover Over TimeCYTK Percentage of Float Shorted Over Time Cytokinetics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202513,950,000 shares $537.91 million -2.7%12.0%7.2 $38.56 3/31/202514,330,000 shares $575.92 million +0.8%12.4%7.9 $40.19 3/15/202514,220,000 shares $630.80 million +1.1%12.3%9 $44.36 2/28/202514,070,000 shares $647.22 million -6.6%12.2%9.6 $46.00 2/15/202515,070,000 shares $695.63 million +10.4%13.1%10.6 $46.16 1/31/202513,650,000 shares $675.13 million -2.7%12.0%10.1 $49.46 1/15/202514,030,000 shares $657.59 million +2.3%12.4%11.6 $46.87 12/31/202413,710,000 shares $644.92 million -0.2%12.1%11.8 $47.04 12/15/202413,730,000 shares $667.96 million -2.1%12.1%11.7 $48.65 11/30/202414,030,000 shares $727.60 million -3.8%12.4%11.8 $51.86 Get the Latest News and Ratings for CYTK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202414,590,000 shares $732.71 million -7.0%12.8%11.8 $50.22 10/31/202415,690,000 shares $800.19 million +1.0%13.8%13.3 $51.00 10/15/202415,540,000 shares $860.61 million -10.3%13.7%12.8 $55.38 9/30/202417,320,000 shares $914.50 million -2.9%15.2%13.9 $52.80 9/15/202417,840,000 shares $996.90 million -2.0%15.7%12.9 $55.88 8/31/202418,210,000 shares $1.04 billion -2.3%16.0%12.8 $57.08 8/15/202418,630,000 shares $1.06 billion +4.5%16.4%9.4 $57.06 7/31/202417,830,000 shares $1.05 billion +2.1%15.7%8.7 $59.01 7/15/202417,460,000 shares $1.00 billion +0.5%15.8%8.8 $57.39 6/30/202417,380,000 shares $941.65 million +8.4%15.7%8.8 $54.18 6/15/202416,040,000 shares $865.04 million -2.3%14.5%8.3 $53.93 5/31/202416,420,000 shares $796.53 million +15.7%14.9%7.2 $48.51 5/15/202414,190,000 shares $858.50 million +3.8%14.1%6.5 $60.50 4/30/202413,670,000 shares $838.24 million -2.6%13.5%7.2 $61.32 4/15/202414,040,000 shares $954.72 million +6.1%13.9%6.9 $68.00 3/31/202413,230,000 shares $927.56 million -10.6%13.3%4.2 $70.11 3/15/202414,800,000 shares $964.81 million +1.9%14.9%3.7 $65.19 2/29/202414,530,000 shares $1.05 billion +5.1%14.6%3.9 $72.24 2/15/202413,830,000 shares $1.09 billion +1.8%14.6%3.9 $78.56 1/31/202413,580,000 shares $1.06 billion -1.2%14.5%3.9 $78.13 1/15/202413,750,000 shares $1.18 billion -8.8%14.7%3.9 $85.60 12/31/202315,080,000 shares $1.26 billion +2.9%16.1%5.1 $83.49 12/15/202314,660,000 shares $528.79 million +9.0%15.7%6.7 $36.07 11/30/202313,450,000 shares $450.31 million -1.8%14.4%8.9 $33.48 11/15/202313,690,000 shares $449.44 million -3.1%14.6%10.1 $32.83 10/31/202314,130,000 shares $492.57 million +2.8%15.4%11.6 $34.86 10/15/202313,750,000 shares $470.39 million +5.3%15.0%13 $34.21 9/30/202313,060,000 shares $384.75 million +4.1%14.2%14.2 $29.46 9/15/202312,550,000 shares $429.59 million +8.1%13.7%15.7 $34.23 8/31/202311,610,000 shares $405.65 million +15.1%13.0%14.2 $34.94Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/15/202310,090,000 shares $330.04 million No Change11.3%12.4 $32.71 7/31/202310,090,000 shares $336.50 million -0.1%11.2%12.1 $33.35 7/15/202310,100,000 shares $352.79 million +1.5%11.3%11.8 $34.93 6/30/20239,950,000 shares $324.57 million +7.9%11.1%11.3 $32.62 6/15/20239,220,000 shares $326.76 million -2.5%10.3%10.2 $35.44 5/31/20239,460,000 shares $356.55 million +0.2%10.5%10.4 $37.69 5/15/20239,440,000 shares $367.69 million No Change10.5%9.4 $38.95 10/31/202211,340,000 shares $495.10 million -8.8%N/A9.9 $43.66 10/15/202212,440,000 shares $571.62 million +2.7%N/A10 $45.95 9/30/202212,110,000 shares $586.73 million +3.8%N/A9.5 $48.45 9/15/202211,670,000 shares $636.13 million -2.9%N/A7.7 $54.51 8/31/202212,020,000 shares $636.58 million -5.7%N/A8.1 $52.96 8/15/202212,740,000 shares $647.57 million +8.7%N/A9.2 $50.83 7/31/202211,720,000 shares $496.11 million -0.8%N/A8.6 $42.33 7/15/202211,810,000 shares $478.31 million +37.8%N/A9.4 $40.50 6/30/20228,570,000 shares $336.72 million +0.5%16.6%7.3 $39.29 6/15/20228,530,000 shares $350.67 million -2.0%16.5%10 $41.11 5/31/20228,700,000 shares $347.13 million -2.6%N/A10.1 $39.90 5/15/20228,930,000 shares $375.15 million +11.5%N/A9.6 $42.01 4/30/20228,010,000 shares $319.36 million +1.0%N/A7.9 $39.87 4/15/20227,930,000 shares $313.71 million +5.7%N/A7.9 $39.56 3/31/20227,500,000 shares $276.08 million +3.7%N/A6.9 $36.81 3/15/20227,230,000 shares $245.39 million -13.1%N/A6.7 $33.94 2/28/20228,320,000 shares $293.86 million +1.2%N/A7.7 $35.32 2/15/20228,220,000 shares $308.91 million +4.2%N/A7.5 $37.58 1/31/20227,890,000 shares $261.87 million -1.5%N/A7.7 $33.19 1/15/20228,010,000 shares $264.33 million +0.8%N/A0 $33.00 12/31/20217,950,000 shares $362.36 million -9.1%N/A8.8 $45.58 12/15/20218,750,000 shares $337.84 million +1.0%N/A10.1 $38.61 11/30/20218,660,000 shares $340.68 million -5.8%N/A10.1 $39.34 11/15/20219,190,000 shares $360.25 million -9.8%N/A10.6 $39.20 10/29/202110,190,000 shares $355.73 million +5.2%N/A12.3 $34.91 10/15/20219,690,000 shares $357.46 million -7.7%N/A11.3 $36.89 9/30/202110,500,000 shares $375.27 million -1.8%N/A5.5 $35.74 9/15/202110,690,000 shares $360.25 million -5.4%N/A5.7 $33.70 8/31/202111,300,000 shares $372.56 million -1.0%N/A6.2 $32.97 8/13/202111,410,000 shares $366.83 million -4.3%N/A6.5 $32.15 7/30/202111,920,000 shares $353.79 million +32.4%N/A6.6 $29.68 7/15/20219,000,000 shares $173.88 million +10.2%N/A5.2 $19.32 6/30/20218,170,000 shares $161.68 million -5.4%12.2%10.8 $19.79 6/15/20218,640,000 shares $192.50 million -4.9%12.9%11.8 $22.28 5/28/20219,080,000 shares $198.22 million -9.6%13.6%11.2 $21.83 5/14/202110,040,000 shares $253.31 million +6.9%N/A10.6 $25.23 4/30/20219,390,000 shares $247.80 million +2.6%N/A10.2 $26.39 4/15/20219,150,000 shares $221.98 million +1.9%N/A0 $24.26 3/31/20218,980,000 shares $200.52 million -7.7%N/A9.6 $22.33 3/15/20219,730,000 shares $222.04 million +5.5%N/A10.1 $22.82 2/26/20219,220,000 shares $183.02 million +0.2%N/A9.2 $19.85 2/12/20219,200,000 shares $209.39 million -3.7%N/A9.8 $22.76 1/29/20219,550,000 shares $191 million -3.5%N/A9.3 $20.00Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 1/15/20219,900,000 shares $196.02 million +6.3%N/A9.6 $19.80 12/31/20209,310,000 shares $189.55 million +12.7%N/A7.4 $20.36 12/15/20208,260,000 shares $175.44 million -7.8%N/A4.8 $21.24 11/30/20208,960,000 shares $153.66 million +1.8%N/A5.4 $17.15 11/15/20208,800,000 shares $145.38 million -6.4%N/A5.5 $16.52 10/30/20209,400,000 shares $145.61 million +3.3%N/A6.1 $15.49 10/15/20209,100,000 shares $150.06 million +3.6%N/A6 $16.49 9/30/20208,780,000 shares $190.09 million +22.3%N/A5.7 $21.65 9/15/20207,180,000 shares $166.72 million -3.8%N/A7.6 $23.22 8/31/20207,460,000 shares $178.74 million +3.5%N/A8.2 $23.96 8/14/20207,210,000 shares $162.37 million -1.2%N/A8.3 $22.52 7/31/20207,300,000 shares $157.83 million -9.2%13.4%7.5 $21.62 7/15/20208,040,000 shares $224.16 million -1.7%14.8%8.2 $27.88 6/30/20208,180,000 shares $192.97 million +6.0%15.0%9.5 $23.59 6/15/20207,720,000 shares $167.76 million -6.3%14.2%8.9 $21.73 5/29/20208,240,000 shares $170.73 million +3.7%15.1%9 $20.72 5/15/20207,950,000 shares $172.04 million +1.9%14.6%8.1 $21.64 CYTK Short Interest - Frequently Asked Questions What is Cytokinetics' current short interest? Short interest is the volume of Cytokinetics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 13,950,000 shares of CYTK short. 12.02% of Cytokinetics' shares are currently sold short. Learn More on Cytokinetics' current short interest. What is a good short interest ratio for Cytokinetics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CYTK shares currently have a short interest ratio of 7.0. Learn More on Cytokinetics's short interest ratio. Which institutional investors are shorting Cytokinetics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cytokinetics: GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, Troluce Capital Advisors LLC, Nomura Holdings Inc., Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Pentwater Capital Management LP, Parallax Volatility Advisers L.P., Susquehanna International Group LLP, HAP Trading LLC, Concourse Financial Group Securities Inc., PEAK6 LLC, JPMorgan Chase & Co., and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cytokinetics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.02% of Cytokinetics' floating shares are currently sold short. Is Cytokinetics' short interest increasing or decreasing? Cytokinetics saw a decline in short interest in April. As of April 15th, there was short interest totaling 13,950,000 shares, a decline of 2.7% from the previous total of 14,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cytokinetics' float size? Cytokinetics currently has issued a total of 119,188,000 shares. Some of Cytokinetics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytokinetics currently has a public float of 116,040,000 shares. How does Cytokinetics' short interest compare to its competitors? 12.02% of Cytokinetics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cytokinetics: Teva Pharmaceutical Industries Limited (2.69%), Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.33%), Dr. Reddy's Laboratories Limited (1.91%), Ascendis Pharma A/S (11.37%), Moderna, Inc. (16.48%), Viatris Inc. (3.96%), Qiagen (2.11%), Roivant Sciences Ltd. (11.68%), Lantheus Holdings, Inc. (10.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Cytokinetics stock? Short selling CYTK is an investing strategy that aims to generate trading profit from Cytokinetics as its price is falling. CYTK shares are trading down $0.42 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cytokinetics? A short squeeze for Cytokinetics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTK, which in turn drives the price of the stock up even further. How often is Cytokinetics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTK, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies TEVA Short Interest Data ITCI Short Interest Data GMAB Short Interest Data RDY Short Interest Data ASND Short Interest Data MRNA Short Interest Data VTRS Short Interest Data QGEN Short Interest Data ROIV Short Interest Data LNTH Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYTK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
